Abstract
Because of the multifactor development of postmenopausal osteoporosis, it is important to implement a comprehensive approach to the prevention and treatment of this pathology. Along with the menopausal hormone therapy, the use of multicomponent drugs plays an important role in correcting osteoporotic changes. These drugs are aimed at compensating for deficiency and deficiency in the body of calcium, vitamin D, as well as osteotropic microelements that regulate calcium metabolism, such as zinc, copper, manganese, boron, magnesium. Complex of these components has osteoprotective effect, increases the effectiveness of preventing the reduction of bone mineral density in women in the postmenopausal period. These can reduce the risk of osteoporosis and associated complications that affect the quality of life.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
